Citation

Peck KR, Ochalek TA, Badger GJ, Sigmon SC. Drug Alcohol Depend. 2020; 208: e107879.

Affiliation

Vermont Center on Behavior and Health, University of Vermont, 1 S. Prospect Street, Burlington, VT 05401, United States.

Copyright

(Copyright © 2020, Elsevier Publishing)

DOI

10.1016/j.drugalcdep.2020.107879

PMID

31991327

Abstract

OBJECTIVE: Although opioid maintenance is a first-line approach for treating opioid use disorder (OUD), suboptimal treatment outcomes have been reported among emerging adults (EAs; 18-25 years of age). In this secondary analysis, we compared treatment outcomes between EAs and older adults (OAs; ≥ 26 years of age) receiving low-barrier, technology-assisted Interim Buprenorphine Treatment (IBT) during waitlist delays to comprehensive opioid maintenance treatment.

METHOD: Participants were 35 individuals with OUD who received IBT consisting of 12-weeks of buprenorphine maintenance with bi-monthly clinic visits and technology-assisted monitoring. At monthly follow-up assessments, participants completed staff-observed urinalysis, the Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI-II), and Addiction Severity Index (ASI).

RESULTS: At study intake, EAs (n = 10) reported greater past-year intravenous drug use and greater employment, legal, and psychiatric severity (p's <.05) compared to OAs (n = 25). Despite these initial differences, there were no significant differences in the percentages of urine specimens testing negative for illicit opioids between EA and OA participants at Study Week 4 (90 % vs. 88 %, p =.99), Week 8 (80 % vs. 76 %, p =.99) or Week 12 (60 % vs. 68 %, p =.71). Relative to their older peers, EAs also demonstrated significantly greater improvements on the BAI, BDI-II, and ASI Employment and Legal subscales (p's <.05).

CONCLUSIONS: Despite presenting with greater past-year intravenous drug use and psychosocial severity relative to OAs, EAs responded favorably to the IBT intervention.

Copyright © 2020 Elsevier B.V. All rights reserved.

Language: en

Keywords

Buprenorphine; Emerging adults; Interim treatment; Opioid use disorder